An interventional study of Transition program in Type 1 Diabetes Mellitus, Obesity and Asthma, sponsored by Universiteit Antwerpen. Active, not recruiting at 1 site in Belgium. Open to participants aged 16 Years to 19 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Universiteit Antwerpen · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Diabetes Mellitus, Type 1 with a site in Belgium — 14 open to participants now, 19 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Belgium.
Among the 106 studies in Diabetes Mellitus, Type 1 with a site in Belgium, this one is the 57th largest by enrollment of the 82 interventional ones that give a count, is one of 4 that started in 2025, is one of 27 with no phase, reaches primary completion later than 7 of the 18 other live ones, and was the 100th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →14 of the 106 studies in Diabetes Mellitus, Type 1 with a site in Belgium are open now. Recruiting first, the newest first:
Sanofi · Sites in Belgium, France, Germany and 3 more countries
Eli Lilly and Company · Sites in Belgium, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in Belgium, United States, Australia and 16 more countries
Ages 1–35
SAb Biotherapeutics, Inc. · Sites in Belgium, United States, Australia and 12 more countries
Ages 5–40
Sanofi · Sites in Belgium, United States, Argentina and 17 more countries
Ages 1–25
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 16 Years to 19 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 26 · Phase 4 3
First in 2000; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 155 across the 82 interventional studies, 188 across the 23 observational. Of the 77 that completed or were terminated, 28 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 106 have an industry lead sponsor. The 10 most frequent:
Universiteit Antwerpen is the lead sponsor of 135 studies on the registry; 32 are open to participants now.
Universiteit Antwerpen has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
7 of the studies in Diabetes Mellitus, Type 1 with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT07145671Universiteit AntwerpenThe COCCOS Study: a Transition Program for Young Persons With Chronic Conditions | 2026-12 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
| NCT04769037Helmholtz Zentrum MünchenSupplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity | 2027-10 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies in Diabetes Mellitus, Type 1 with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study is undertaken to examine the feasibility of the newly developed transition program in adolescents with type 1 diabetes, asthma and obesity in a multicentric setting. Specific objectives for this study are: (1) examining the impact of the program in terms of patient-reported health outcomes, (2) examining patients' and healthcare providers' experiences related to the program implementation process, and (3) examining the impact of the program in terms of cost-effectiveness.
Chronic conditions are increasingly common in youth, with 10-25% affected and over 85% reaching adulthood. This rise stems from higher incidence of conditions like diabetes and improved survival of congenital diseases. These young patients face a lifelong risk of complications, requiring continuous, age-appropriate care. A well-managed transfer from pediatric to adult care is essential, yet up to half of adolescents lack adequate preparation. Poor transitions can lead to care disruption, worse health outcomes, and higher costs. Structured transition programs (TPs) can improve self-management, adherence, and health outcomes, while reducing costs. However, implementation and long-term integration of TPs remain limited, especially for common chronic conditions. Following the development of a TP through Experience-Based Co-Design in the COCCOS project, the next phase involves a feasibility study to assess its preliminary impact.
A multicenter, quasi-experimental pre-test post-test study will assess a co-designed transition program at two Belgian hospitals (UZA and UZ Ghent), comparing it to usual care. AYAs aged 17-18 with type 1 diabetes, asthma, or obesity will be recruited (n=150). The intervention group will receive the TP over 9-15 months; the control group (CG) will receive usual care. Assessments occur at baseline, transfer, and 4 months post-transfer.
The TP includes four stages:
The primary outcome of the study is transition readiness, measured using the Transition Readiness Assessment Questionnaire (TRAQ). Secondary outcomes include patient empowerment (GYPES), medication adherence (MARS-5), quality of life (EQ-5D-5L), and anxiety and depression (HADS). Clinical indicators such as emergency visits, missed consultations, and disease-specific biomarkers will also be collected. Data will be analyzed using descriptive statistics, paired and independent t-tests, and multivariable regression analyses. To account for baseline differences between groups, inverse probability treatment weighting (IPTW) will be applied. Significance will be set at p \< 0.05. A process evaluation will be conducted alongside the effect evaluation to understand how the TP was implemented and received by AYAs, families, and healthcare providers. Data will be gathered using observations, satisfaction questionnaires, and semi-structured interviews. Evaluation will focus on fidelity, dose delivered and received, reach, contextual influences, and any adaptations made during the intervention. Qualitative data will be analyzed thematically using NVivo software. The cost-effectiveness of the TP will be assessed using a health economic model, developed in accordance with ISPOR guidelines. Cost data will include implementation expenses and healthcare utilization, while effectiveness data will focus on quality-adjusted life years (QALYs) derived from the EQ-5D-5L. The model will calculate an incremental cost-effectiveness ratio (ICER) comparing the TP with usual care. Sensitivity analyses and bootstrapping will be performed to address uncertainty, and cost-effectiveness acceptability curves will be generated to assess the probability of the TP being cost-effective at various willingness-to-pay thresholds.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For participants in the intervention group (IG):
For participants in the control group (CG):
Exclusion criteria:
Applicable for both CG and IG:
- patients with severe mental, cognitive or neurological problems will be excluded
A transition program (TP) was developed, as part of the first work package of the COCCOS project, in close collaboration with stakeholders (i.e., AYA patients, parents and HCPs) based on participatory action research methods (i.e., Experience-Based Co Design, including photovoice). Based on this study, the developed TP entailed four key moments: (i) a transition consultation, (ii) a consultation without parents, (iii) a joint consultation, and (iv) a feedback moment. Over a course of approximately 9-15 months (this can differ considering different pathologies have different care trajectories (e.g., frequency of consultations)), AYAs will receive an intensive person-centered transition program consisting of the four key moments.
Other: Transition program
Participants in this arm will receive standard of care.
Transition Consultation: Pediatric HCP introduces the transition process to AYA and family. A contact person is assigned (ideally the AYA's trusted HCP), along with someone from the AYA's personal network. Key points are recorded in the Individualized Transition Plan (ITP). Independent Visit: AYA has a solo consultation (parents briefly step out). They complete the Ready Steady Go checklist. The ITP is updated, and concerns are discussed. Joint Consultation: Pediatric and adult HCPs meet with the AYA. A new adult contact is assigned, and the AYA picks a pediatric contact for feedback. Checklist is completed again. Feedback Moment: After transfer, the pediatric contact checks in. The checklist guides discussion; feedback is shared across teams, and follow-up arranged if needed.
Readiness to transition - TRAQ 6.0
Transition Readiness Assessment Questionnaire (TRAQ), version 6.0. As the primary aim of the TP is to prepare AYAs for transition to adult care, the primary outcome is transition readiness. This is assessed using the TRAQ (version 6.0) \[25,26,28\]. The TRAQ is a 20-item self-report instrument designed to evaluate the skills necessary for a successful transition. It covers four domains: (1) medication management, (2) appointment keeping, (3) tracking health issues, and (4) talking with providers. In addition, it includes two global transition readiness items. Items are scored on a 5-point Likert scale, with total scores ranging from 0 to 53, where higher scores indicate greater transition readiness \[28\]. Prior to use in this study, the TRAQ will be forward-backward translated into Dutch (Flemish) to ensure linguistic and cultural validity.
Time frame: 12 months
Generic Youth Patient Empowerment Scale (GYPES)
The Generic Youth Patient Empowerment Scale (GYPES) is a 15-item questionnaire designed to assess the level of empowerment in young patients with chronic conditions. Using a 5-point Likert scale, it yields a total score ranging from 15 to 75. Higher scores reflect greater empowerment, indicating that the young person feels more knowledgeable, confident, and involved in managing their healthcare, while lower scores suggest a need for additional support to strengthen self-management and engagement.
Time frame: 12 months
EQ-5D-5L
The EQ-5D-5L is a standardized questionnaire used to assess health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on five levels of severity, and responses are combined into a single health profile that can be converted into an index score, typically ranging from less than 0 (representing health states worse than death) to 1 (representing full health). Higher scores reflect better perceived quality of life, while lower scores indicate greater health-related challenges.
Time frame: 12 months
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire used to assess levels of anxiety and depression in individuals with physical health problems. It consists of two subscales-anxiety and depression-each with 7 items, scored from 0 to 21. Higher scores indicate greater levels of anxiety or depression, with scores of 0-7 considered normal, 8-10 borderline, and 11-21 indicating clinically significant symptoms.
Time frame: 12 months
Medication Adherence Report Scale (MARS-5)
Medication adherence is evaluated using the MARS-5, a brief 5-item measure assessing both intentional and unintentional non-adherent behaviours. Items address behaviours such as forgetting to take medication or deliberately altering doses. Each item is rated on a 5-point Likert scale, with higher scores indicating better adherence. The MARS-5 is widely used due to its simplicity and sensitivity to different types of non-adherence.
Time frame: 12 months
Cost-effectiveness
Costs related to the implementation of the TP will be systematically collected. These will include personnel costs associated with the time investment of healthcare professionals involved in the program (e.g., physician, nurses, psychologists, dieticians, and diabetes educators), as well as costs related to multidisciplinary team meetings. In addition, material costs will be considered, including printed educational materials and other resources used within the intervention. Healthcare resource use will be estimated using published data on healthcare utilization patterns, combined with unit costs derived from the National Institute for Health and Disability Insurance (NIHDI) nomenclature of healthcare services. This approach will allow estimation of healthcare costs associated with outpatient visits, hospitalizations, and other reimbursed services. Health outcomes will be derived from the EQ-5D-5L utility values.
Time frame: 18 months
Process evaluation
Several programme dimensions will be examined, including: intervention fidelity (the extent to which the TP was delivered as intended with consistent quality), dose (the extent to which the TP was delivered by healthcare providers and received by patients and families), reach (the proportion and characteristics of patients who participated), context (factors that facilitated or hindered TP uptake), and change (changes made by care team during implementation)
Time frame: 18 months
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 21 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.